Mesenchymal Stem Cells: Cell Fate Decision to Osteoblast or Adipocyte and Application in Osteoporosis Treatment.
Hu L, Yin C, Zhao F, Ali A, Ma J, Qian A. · 2018
Read Mesenchymal Stem Cells: Cell Fate Decision to Osteoblast or Adipocyte and Application in Osteoporosis Treatment. by Hu L, Yin C, Zhao F, Ali A, Ma J, Qian A. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5855582.txt.
Introduction
Hu and co-authors review how mesenchymal stem cells choose their fate. Their article appeared in the International Journal of Molecular Sciences. These stem cells can become bone cells or fat cells. In osteoporosis, the balance tips toward fat cells. Bone mass then falls and fracture risk rises. The review asks what controls that choice at the molecular level.
The authors sum up signals that push cells toward bone or fat. They also review cell therapy trials for osteoporosis care. Stem cells have been tested in lab studies and in patients. The authors see this knowledge as a route to new treatments. Readers get the disease background and the therapy outlook together.
Catalog record
| CREATOR | Hu L, Yin C, Zhao F, Ali A, Ma J, Qian A. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 72 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Mesenchymal Stem Cells: Cell Fate Decision to Osteoblast or Adipocyte and Application in Osteoporosis Treatment By Lifang Hu, Chong Yin, Fan Zhao, Arshad Ali, Jianhua Ma, Airong Qian Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms19020360 ABSTRACT Abstract Osteoporosis is a progressive skeletal disease characterized by decreased bone mass and degraded bone microstructure, which leads to increased bone fragility and risks of bone fracture. Osteoporosis is generally age related and has become a major disease of the world. Uncovering the molecular mechanisms underlying osteoporosis and developing effective prevention and therapy methods has great significance for human health. Mesenchymal stem cells (MSCs) are multipotent cells capable of differentiating into osteoblasts, adipocytes, or chondrocytes, and have become the favorite source of cell-based therapy. Evidence shows that during osteoporosis, a shift of the cell differentiation of MSCs to adipocytes rather than osteoblasts partly contributes to osteoporosis. Thus, uncovering the molecular mechanisms of the osteoblast or adipocyte differentiation of MSCs will provide more understanding of MSCs and perhaps new methods of osteoporosis treatment. The MSCs have been applied to both preclinical and clinical studies in osteoporosis treatment. Here, we review the recent advances in understanding the molecular mechanisms regulating osteoblast differentiation and adipocyte differentiation of MSCs and highlight the therapeutic application studies of MSCs in osteoporosis treatment. This will provide researchers with new insights into the development and treatment of osteoporosis. Keywords: osteoporosis, mesenchymal stem cell, osteoblast, adipocyte, cell therapy 1. INTRODUCTION Osteoporosis is a systemic bone disease characterized by low bone mass and the deteriorative microarchitecture of bone tissue, which leads to increased bone fragility and the risk of bone fracture [1,2]. As many countries encounter the aging of their populations, osteoporosis has become a significant health concern of the world. In the years 2006 and 2007, it has been reported that osteoporosis affected 200 million women worldwide and caused more than 8.9 million fractures annually, giving rise to an osteoporotic fracture every 3 seconds [3]. At present, more and more people are suffering from osteoporosis. The National Osteoporosis Foundation (NOF) has reported that one in two women and up to one in four men aged 50 and older will break a bone due to osteoporosis. Therefore, osteoporosis has become a major disease of the world and seriously affects people’s health. Evidence shows that age-related osteoporosis develops in association with reduced bone formation and increased marrow fat accumulation [4,5,6,7]. During osteoporosis development, bone marrow mesenchymal stem cells (MSCs) exhibit reduced capacity to differentiate into osteoblasts and an increased capacity to differentiate into adipocytes, which results in a reduction in bone formation and an increase in marrow fat accumulation [4,8]. It is demonstrated that the shift of cell differentiation of MSCs to adipocytes rather than osteoblasts partly contributes to osteoporosis [8,9]. Therefore, understanding the molecular mechanisms regulating the switch between osteoblast differentiation and adipocyte differentiation of MSCs is important for both understanding osteoporosis occurrence and developing new therapy methods for osteoporosis. For osteoporosis treatment, the aim is to maintain the normal bone mass. The current osteoporosis therapies are mainly the drug-based agents that inhibit bone resorption or improve bone anabolism. Bisphosphonates, the most widely used agents for osteoporosis treatment, target osteoclast and inhibit bone resorption [10,11,12]. Denosumab, an antibody to the receptor activator of nuclear factor-κB ligand (RANKL), is also one main antiresorptive agent [13,14,15]. There are a few bone anabolic agents. Teriparatide, a parathyroid hormone (PTH) analog, is an anabolic agent that functions by inducing bone formation [16]. In addition, romosozumab, an antibody to sclerostin, is a new anabolic agent that both enhances bone formation and inhibits bone resorption [17,18]. However, most antiresorptive agents showed side effects during the treatment of osteoporosis [19,20] and there are fewer bone anabolic agents. Therefore, there is an urgent need to develop new treatments for osteoporosis. With the rapid development of cell-based therapy, MSCs have become the focus of new treatments of osteoporosis. Here, we review the current understanding of MSCs and summarize the recent advances of the molecular mechanisms regulating osteoblast and adipocyte differentiation of MSCs. Given the special role of MSCs in osteoporosis and their multipotency, MSCs-based preclinical and clinical studies for osteoporosis are introduced by focusing on bone marrow MSCs (BM-MSCs) and adipose tissue-derived MSCs (AD-MSCs). This review will provide researchers an increase understanding of MSCs and give guidance for the future research on osteoporosis treatment. 2. MESENCHYMAL STEM CELLS (MSCS) AND BONE MARROW MSCS (BM-MSCS) IN OSTEOPOROSIS DEVELOPMENT MSCs, also known as marrow stromal cells, are multipotent adult stem cells that exist in almost all post-natal organs and tissues, such as bone marrow, fat tissues, liver, muscle, and the umbilical cord [21,22]. MSCs were first discovered in bone marrow by Friedenstein et al. [23]. They found the non-hematopoietic stem cell population in bone marrow and observed that the cells were adherent, spindle-shaped, and able to form single-cell-derived colonies [23]. Further, Friedenstein et al. reported that the non-hematopoietic stem cells showed stem-like characteristics [24]. Thereafter, MSCs were isolated from other tissues, including adipose [25,26], umbilical cord [27], muscle [28], and dental pulp [29]. These demonstrate the ubiquitous distribution of MSCs. MSCs are capable of self-renewing and differentiating into multiple cell lineages, including osteoblasts, adipocytes, and chondrocytes [30,31] (Figure 1). To define MSCs in a common standard, the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy has proposed the minimal criteria to define human MSCs [32]. First, MSCs must be plastic-adherent when maintained in standard culture conditions. Second, MSCs must express CD105, CD73, and CD90, and lack expression of CD45, CD34, CD14, CD11b, CD79α, CD19, and human leukocyte antigen-antigen D related (HLA-DR) surface molecules. Third, MSCs must differentiate to osteoblasts, adipocytes, and chondroblasts in vitro. As there are no specific markers for MSCs, both positive markers and negative markers are applied to identify MSCs. The positive markers are expressed by MSCs, while negative markers should not expressed by MSCs. Accordingly, in humans, Stro-1, CD29, CD44, CD73, CD90, CD105, CD146, and SSEA4 are positive combination markers for MSCs [33,34], while in mice, Sca-1, CD29, CD44, and CD105 are the positive markers [34]. Additionally, there are negative markers that distinguish MSCs from hematopoietic or endothelial cells, including CD45, CD34, CD14, CD11b, CD79α, CD19, and HLA-DR surface molecules [32] (Figure 1). [Figure: Schematic diagram of the characteristics of mesenchymal stem cells (MSCs). There are both positive markers and negative markers for identifying MSCs. MSCs possess the characteristics of self-renewing and differentiating into multiple cell types, including osteoblast, adipocyte, chondrocyte, myocyte, and fibroblast.] BM-MSCs are MSCs residing in bone marrow and have multiple differentiation potentials. BM-MSCs can differentiate into osteoblasts and adipocytes, which play an important role in maintaining normal bone stability. It has been demonstrated that the altered proliferation and differentiation of BM-MSCs is one main cause of osteoporosis [35,36]. Moerman et al. have reported that in old mice, the adipocytes are increased and osteoblasts are decreased, accompanied by reduced bone mineral density (BMD) [4]. Further study on the differentiation potential of MSCs isolated from old (26-month-old) mice showed a high ability to differentiate into adipocytes rather than osteoblasts [4]. Shen et al. indicated an inverse relationship between pelvic bone marrow adipose tissue and BMD, suggesting that low BMD may be due